NCT01460719View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 24, 2012

Primary Completion Date

September 25, 2012

Study Completion Date

September 25, 2012

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

V212

V212 viral antigen for HZ

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01460719 - A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) | Biotech Hunter | Biotech Hunter